Neurocrine Biosciences, Inc. (NBIX)
132.95
-2.84
(-2.09%)
USD |
NASDAQ |
Jan 12, 12:39
Neurocrine Biosciences Research and Development Expense (Quarterly): 250.00M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Pfizer Inc. | 2.492B |
| Masimo Corp. | 30.50M |
| Insulet Corp. | 77.20M |
| Marker Therapeutics, Inc. | 2.346M |
| CapsoVision, Inc. | 6.09M |